caseintelcaseintel
← Back to Dashboard
Litigation Stage Tracker
Active Filing

Cartiva SCI

OpenFILING
MDL 3172Device
400+
Total Cases

Causation

Plaintiffs allege the Cartiva SCI device is defectively designed. The PVA hydrogel implant degrades in vivo, losing structural integrity and fragmenting within the first metatarsophalangeal joint. Implant failure causes chronic inflammation, bone cyst formation, osteolysis (bone loss), and severe pain requiring revision surgery — typically the fusion procedure the implant was meant to avoid. Post-market surveillance and clinical registries show failure rates significantly higher than the 10-year data presented in the original 510(k) clearance. Plaintiffs argue Stryker and Cartiva knew or should have known about elevated failure rates from European market data before aggressively marketing in the US.

Defendants

EntityRoleNote
Stryker CorporationCurrent ManufacturerAcquired Cartiva Inc. in 2020 for $430M — assumed all product liabilities
Cartiva Inc.Original ManufacturerDeveloped and initially marketed the SCI device before Stryker acquisition

Litigation Timeline

2016
Cartiva SCI receives FDA 510(k) clearance for US market
2020
Stryker acquires Cartiva Inc. for $430M
2022
Adverse event reports accumulate; first lawsuits filed
2025
Bellwether discovery pool selected; mediation initiated
May 26, 2026
Bellwether trial scheduled

Intelligence Signals

Courtcourt
Meta Platforms, Inc. v. Bonta
Courtcourt
Dean v. Uber Technologies Incorporated
Courtcourt
IN RE: Shell Eggs Antitrust Litigation
Courtcourt
BAILEY v. JOHNSON & JOHNSON

Key Facts

Status
active

Geographic Exposure

·D. Ariz. (MDL 3172)
·Nationwide filing — all 50 states
·Parallel state court filings in NJ and CA

Eligibility Criteria

  • Had a Cartiva SCI device implanted in the big toe joint
  • Experienced implant failure, migration, or disintegration
  • Suffered chronic pain, bone erosion, or joint deterioration after implantation
  • Required revision surgery (typically fusion) to address failed implant